Summary
Global Autoimmune Disease Diagnostics Market Size
The Autoimmune Disease Diagnostics Market is expected to expand from US$5.70 billion in 2024 to US$10.63 billion by 2033 at a CAGR of 7.17% between 2025 and 2033. The rising cases of autoimmune diseases, progress in diagnostic technologies, and an increased awareness of the early detection of the conditions fuel this growth. Rising demands for more precise, tailored diagnostic tests spur on the market, especially within the expanding healthcare infrastructure across different regions.
Autoimmune Disease Diagnostics Industry Overview
Autoimmune disease diagnostics is the process of detecting and diagnosing autoimmune disorders, which occur when the immune system mistakenly attacks healthy cells. These diseases include conditions like rheumatoid arthritis, lupus, multiple sclerosis, and Type 1 diabetes. Diagnosing autoimmune diseases is essential to ensure proper treatment and management because their symptoms are similar to many other diseases and cannot easily be pinpointed to identify the root cause.
Diagnostic tools used in the detection of autoimmune diseases include blood tests, ELISA, and immunofluorescence assays, which detect specific antibodies, markers, or proteins associated with autoimmune diseases. Other diagnostic techniques include imaging tests and tissue biopsies to assess organ involvement. The use of autoimmune disease diagnostics has increased due to the rising prevalence of these conditions, which are often chronic and require long-term management. Early detection through these diagnostic methods helps manage symptoms, prevent complications, and improve patients' quality of life. Advanced technologies have also enabled more accurate and personalized diagnostics for autoimmune diseases.
Growth Drivers in the Autoimmune Disease Diagnostics Market
Increasing Prevalence of Autoimmune Diseases
The growing incidence of autoimmune diseases is one of the major drivers for the autoimmune disease diagnostics market. With conditions like rheumatoid arthritis, lupus, and Type 1 diabetes being more common, there is a higher demand for accurate and early diagnostic tools. The awareness about autoimmune diseases and the better diagnostic capabilities encourage people to seek early detection, further contributing to market growth and the adoption of advanced diagnostic technologies in healthcare settings.
Advances in diagnostic technology
Advances in technology include highly precise and automated diagnostic tests. Other improved diagnostic tools, for instance, advanced blood tests, increased sensitivity, and specificity offer higher detection and sensitivity biomarker methods. These increase earlier and more accurate detection, which is followed by a more informed treatment plan. Improvements in the speed and accuracy of detection in cases of autoimmune diseases due to inclusion of artificial intelligence and machine learning in diagnostic tools hasten the growth rate.
Rising Healthcare Awareness and Early Detection
Growing health consciousness, particularly toward earlier detection, is the greatest driving force behind the market for autoimmune disease diagnostics. A better understanding of the risks and symptoms of autoimmune diseases raises the chances of patients coming forward for diagnostic tests. The early detection of disease often translates into more effective treatment because the chances of complications would be minimal. With increasing healthcare systems focusing on preventative care and early intervention, the demand for advanced solutions for the diagnosis of autoimmune diseases will increase.
Challenges in the Autoimmune Disease Diagnostics Market
High Cost of Diagnostic Tests
The main challenge in the autoimmune disease diagnostics market is the high price of advanced diagnostic tests. Many of the newer technologies are expensive, such as genetic and high-end blood tests. This makes them inaccessible in low-income regions, hence delaying diagnosis and treatment, especially among patients with inadequate insurance coverage or access to healthcare facilities that offer such tests, thereby hindering market growth.
Lack of Standardized Testing Methods
Another challenge in the market of autoimmune disease diagnostics is that the testing methods in various regions are not standardized. Autoimmune diseases are complex and overlapping with other diseases. So, their diagnosis becomes complicated. In the absence of universally accepted and standardized diagnostic criteria, variations in test results are common, and a delayed diagnosis can occur. Also, lack of uniformity in diagnostic procedures from different healthcare providers complicates the accurate detection and management of autoimmune diseases.
Autoimmune Therapeutic and Monitoring Equipment Market
The growth of Autoimmune Therapeutic and Monitoring Equipment Market is due to the increase in prevalence cases with autoimmune diseases that require an active management process and monitoring process. Devices include therapeutic apparatuses like infusion pumps, biologic therapies, as well as monitoring equipment such as monitors for blood pressure, in addition to diagnostic equipment in terms of tracking the course of a disease. Drivers in the market are advancements in personalized medicine and the increasing demand for monitoring at home. Additionally, better and more precise treatments create the need for improved healthcare systems. Increasing awareness and improvement in diagnostic capabilities enhance growth in the market.
Localized Autoimmune Diseases Market
The Localized Autoimmune Diseases Market deals with autoimmune diseases mainly affecting specific organs or tissues, such as localized scleroderma or autoimmune thyroid disorders. These conditions require specific treatments involving the usage of immunosuppressants, biologics, and local interventions-corticosteroid injections, in certain cases. Market research into these diseases has further witnessed a surge owing to increases in prevalence rates, better and faster emerging targeted therapy results, and increasing knowledge levels around the presence of an auto immune condition.
Diabetes Diagnostic Tests Market
The Diabetes Diagnostics Market is the fastest growing segment in the global healthcare industry, supported by a rising prevalence of diabetes, especially type 2 diabetes, and the need for early detection and management. Diagnosing and managing diabetes require a number of diagnostic tools including glucose meters, continuous glucose monitoring systems, and A1C testing kits. This kind of monitoring can better track blood glucose, hence help patients and providers better manage the disease. Another advancement that drives the market includes the development of non-invasive glucose monitoring devices, as well as point-of-care testing solutions. Expanding knowledge about diabetes complications and global healthcare spending also expand the market for diabetes diagnostics.
Hospitals Autoimmune Disease Diagnostics Market
The hospital is emerging as an autoimmune disease diagnostic market as it remains one of the major diagnostic centers of autoimmune diseases through modern diagnostic technologies. With the increase in autoimmune disorders such as rheumatoid arthritis, lupus, and multiple sclerosis, more accurate testing techniques, like blood tests, biopsy procedures, and imaging techniques, are being used in hospitals. The need for hospitals to use advanced equipment in diagnosing autoimmune diseases through specialized diagnostic equipment and well-developed health infrastructure promotes the growth of autoimmune disease diagnostics. Accurate tests for early detection further increase the chances of effective treatments, thus further propelling the market.
Canada Autoimmune Disease Diagnostics Market
The Canada Autoimmune Disease Diagnostics Market is increasing due to increased prevalence of autoimmune diseases like rheumatoid arthritis, lupus, and Type 1 diabetes. High demand for early and accurate diagnosis has led to increasing usage of advanced diagnostic tools such as blood tests, biomarkers, and imaging techniques. Canada has one of the world's most advanced health systems with personalized medicine and precision diagnostics now gaining increased prominence. This, along with increasing knowledge on the existence of auto-immunity and diagnostic technological innovations is also further pushing up the demand in this market. May 2024, Augurex and New Day Diagnostics are proud to partner on SPINEstatTM, a next generation, multiplex biomarker assay designed to change how ankylosing spondylitis (AS) is managed.
United Kingdom Autoimmune Disease Diagnostics Market
The UK's Autoimmune Disease Diagnostics Market is growing, primarily due to the growing prevalence of autoimmune diseases and increasing focus on early and accurate diagnosis. As more people fall victim to diseases such as rheumatoid arthritis, lupus, and multiple sclerosis, demand for advanced diagnostic tools, including blood tests, imaging techniques, and biomarker analysis, is rising. The UK's well-established healthcare infrastructure, advancements in diagnostic technologies, and rising patient awareness are driving the market forward. In addition, ongoing research and innovation in diagnostic solutions are expected to enhance the market's growth further. July 2024, AliveDx, a global in vitro diagnostics company, has launched LumiQ™, an automated immunofluorescence assay solution. This development enables AliveDx to offer a differentiated, ready-to-go solution for autoimmune diagnostics, based on LumiQ IFA and innovative MosaiQ planar microarray technology.
India Autoimmune Disease Diagnostics Market
The India Autoimmune Disease Diagnostics Market is growing due to the growing prevalence of autoimmune diseases, such as rheumatoid arthritis, lupus, and multiple sclerosis. Health awareness has grown over the years, particularly in urban areas, demanding the need for accurate tests of blood tests, biomarkers, and advanced imaging techniques. Furthermore, an increase in health infrastructure, government schemes for better access to health services, and increased adoption of personalized medicine are contributing to this growth. Affordable diagnostic technologies launched in the market have also supported the increasing demand for autoimmune disease diagnostics in India. June 2022, Quotient Limited, a diagnostics company, collaborated with Theradiag, the leader in autoimmune disease testing, to improve the use of Quotient's MosaiQ platform for the diagnosis of autoimmune diseases.
Saudi Arabia Autoimmune Disease Diagnostics Market
The Saudi Arabia Autoimmune Disease Diagnostics Market is expanding as the incidence of autoimmune diseases, including rheumatoid arthritis and lupus, increases in the country. The growing awareness of these diseases and innovative diagnostic technologies are increasing demand for more accurate and sensitive early detection methods. Saudi Arabia has a well-developed infrastructure of healthcare, and changing trends toward advanced diagnostic technology, such as biomarkers and imaging, further increase market growth. Government efforts to better access and quality of care also contribute to the growth of autoimmune disease diagnostics in the country.
Product – Market breakup in 3 viewpoints:
1. Therapeutic & Monitoring Equipment
2. Diagnostics Equipment
3. Drugs
Types – Market breakup in 2 viewpoints:
1. Systemic
2. Localized
Indication – Market breakup in 5 viewpoints:
1. Rheumatic Disease
2. Diabetes
3. Multiple Sclerosis
4. Inflammatory Bowel Disease
5. Others
End-Users – Market breakup in 3 viewpoints:
1. Hospitals
2. Diagnostics Centers
3. Others
Countries – Market breakup from 25 Country viewpoints:
1. North America
1.1 United States
1.2 Canada
2. Europe
2.1 France
2.2 Germany
2.3 Italy
2.4 Spain
2.5 United Kingdom
2.6 Belgium
2.7 Netherlands
2.8 Turkey
3. Asia Pacific
3.1 China
3.2 Japan
3.3 India
3.4 South Korea
3.5 Thailand
3.6 Malaysia
3.7 Indonesia
3.8 Australia
3.9 New Zealand
4. Latin America
4.1 Brazil
4.2 Mexico
4.3 Argentina
5. Middle East & Africa
5.1 Saudi Arabia
5.2 UAE
5.3 South Africa
All the Key players have been covered from 3 Viewpoints:
• Overview
• Recent Developments
• Revenue Analysis
Company Analysis:
1. Abbott Laboratories
2. Bio-Rad Laboratories
3. Roche Diagnostics
4. Siemens Healthineers
5. Bio Merieux SA
6. Myriad Genetics, Inc.
7. Quest Diagnostics Incorporated
8. Thermo Fisher Scientific Inc.
ページTOPに戻る
Table of Contents
1. Introduction
2. Research Methodology
3. Executive Summary
4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges
5. Global Autoimmune Disease Diagnostics Market
6. Market Share
6.1 By Product
6.2 By Type
6.3 By Indication
6.4 By End Users
6.5 By Country
7. Product
7.1 Therapeutic & Monitoring Equipment
7.2 Diagnostics Equipment
7.3 Drugs
8. Type
8.1 Systemic
8.2 Localized
9. Indication
9.1 Rheumatic Disease
9.2 Diabetes
9.3 Multiple Sclerosis
9.4 Inflammatory Bowel Disease
9.5 Others
10. End Users
10.1 Hospitals
10.2 Diagnostics Centers
10.3 Others
11. Country
11.1 North America
11.1.1 United States
11.1.2 Canada
11.2 Europe
11.2.1 France
11.2.2 Germany
11.2.3 Italy
11.2.4 Spain
11.2.5 United Kingdom
11.2.6 Belgium
11.2.7 Netherlands
11.2.8 Turkey
11.3 Asia Pacific
11.3.1 China
11.3.2 Japan
11.3.3 India
11.3.4 South Korea
11.3.5 Thailand
11.3.6 Malaysia
11.3.7 Indonesia
11.3.8 Australia
11.3.9 New Zealand
11.4 Latin America
11.4.1 Brazil
11.4.2 Mexico
11.4.3 Argentina
11.5 Middle East & Africa
11.5.1 Saudi Arabia
11.5.2 UAE
11.5.3 South Africa
12. Porter’s Five Analysis
12.1 Bargaining Power of Buyers
12.2 Bargaining Power of Suppliers
12.3 Degree of Rivalry
12.4 Threat of New Entrants
12.5 Threat of Substitutes
13. SWOT Analysis
13.1 Strength
13.2 Weakness
13.3 Opportunity
13.4 Threat
14. Companies Analysis
14.1 Abbott Laboratories
14.1.1 Overview
14.1.2 Recent Development
14.1.3 Financial Insights
14.2 Bio-Rad Laboratories
14.2.1 Overview
14.2.2 Recent Development
14.2.3 Financial Insights
14.3 Roche Diagnostics
14.3.1 Overview
14.3.2 Recent Development
14.3.3 Financial Insights
14.4 Siemens Healthineers
14.4.1 Overview
14.4.2 Recent Development
14.4.3 Financial Insights
14.5 BioMerieux SA
14.5.1 Overview
14.5.2 Recent Development
14.5.3 Financial Insights
14.6 Myriad Genetics, Inc.
14.6.1 Overview
14.6.2 Recent Development
14.6.3 Financial Insights
14.7 Quest Diagnostics Incorporated
14.7.1 Overview
14.7.2 Recent Development
14.7.3 Financial Insights
14.8 Thermo Fisher Scientific Inc.
14.8.1 Overview
14.8.2 Recent Development
14.8.3 Financial Insights
